Antimicrobial Susceptibility Trends Among Gram-Negative Bacilli Causing Bloodstream Infections: Results from the China Antimicrobial Resistance Surveillance Trial (CARST) Program, 2011-2020
- PMID: 35517902
- PMCID: PMC9064452
- DOI: 10.2147/IDR.S358788
Antimicrobial Susceptibility Trends Among Gram-Negative Bacilli Causing Bloodstream Infections: Results from the China Antimicrobial Resistance Surveillance Trial (CARST) Program, 2011-2020
Abstract
Purpose: The antimicrobial resistance profiles of gram-negative bacilli causing bloodstream infections have changed over time, while comprehensive and real-time surveillance data are limited in China. This study aimed to review the antimicrobial susceptibility trends among main gram-negative bacilli isolated from blood specimens in China.
Methods: From 2011 to 2020, a total of 4352 non-duplicate isolates were collected from 21 tertiary hospitals in 18 provinces or cities across China. Antimicrobial susceptibility testing was conducted by the agar dilution method recommended by the Clinical and Laboratory Standards Institute (CLSI), and the results were interpreted using CLSI criteria.
Results: During this 10-year surveillance period, meropenem and imipenem were the most effective agents against Escherichia coli (resistance remaining <5%). The proportion of ESBL-producing isolates in carbapenem-susceptible E. coli displayed a decreasing trend (from 72.9% to 51.2%). The resistance rates of Klebsiella pneumoniae to meropenem and imipenem increased from 3.3% and 1.6% in the 2011-12 period to 15.0% and 15.4% in the 2019-20 period, respectively. Carbapenems and amikacin were the most active agents against Enterobacter cloacae. The resistance rates of Pseudomonas aeruginosa to meropenem and imipenem increased from 13.1% and 17.7% in the 2015-16 period to 24.5% and 21.0% in the 2019-20 period, respectively. Few agents showed activity against Acinetobacter baumannii. The frequency of imipenem-non-susceptible A. baumannii remained stable (remaining ~70%).
Conclusion: The rapid spread of carbapenem-resistant K. pneumoniae has been serious in recent years. Conversely, the prevalence of ESBL-producing isolates was decreased. Carbapenems are still effective against gram-negative bacilli causing BSIs, except for A. baumannii. More attention should be given to A. baumannii, considering its high resistance against different classes of antimicrobials.
Keywords: A. baumannii; ESBL; Enterobacterales; P. aeruginosa; carbapenem-resistance.
© 2022 Yan et al.
Conflict of interest statement
The authors report no conflicts of interest in this work.
Figures
Similar articles
-
[Antimicrobial resistance of Gram-negative bacilli isolated from 13 teaching hospitals across China].Zhonghua Yi Xue Za Zhi. 2013 May 14;93(18):1388-96. Zhonghua Yi Xue Za Zhi. 2013. PMID: 24025503 Chinese.
-
Distribution and antimicrobial resistance analysis of gram-negative bacilli isolated from a tertiary hospital in Central China: a 10-year retrospective study from 2012 to 2021.Front Microbiol. 2023 Dec 4;14:1297528. doi: 10.3389/fmicb.2023.1297528. eCollection 2023. Front Microbiol. 2023. PMID: 38111644 Free PMC article.
-
Long-Term Continuous Antimicrobial Resistance Surveillance Among Nosocomial Gram-Negative Bacilli in China from 2010 to 2018 (CMSS).Infect Drug Resist. 2020 Jul 28;13:2617-2629. doi: 10.2147/IDR.S253104. eCollection 2020. Infect Drug Resist. 2020. PMID: 32801799 Free PMC article.
-
Sulopenem: An Intravenous and Oral Penem for the Treatment of Urinary Tract Infections Due to Multidrug-Resistant Bacteria.Drugs. 2022 Apr;82(5):533-557. doi: 10.1007/s40265-022-01688-1. Epub 2022 Mar 16. Drugs. 2022. PMID: 35294769 Review.
-
Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli.Drugs. 2019 Feb;79(3):271-289. doi: 10.1007/s40265-019-1055-2. Drugs. 2019. PMID: 30712199 Review.
Cited by
-
High prevalence of carbapenem-resistant Pseudomonas aeruginosa and identification of a novel VIM-type metallo-β-lactamase, VIM-92, in clinical isolates from northern China.Front Microbiol. 2025 Feb 26;16:1543509. doi: 10.3389/fmicb.2025.1543509. eCollection 2025. Front Microbiol. 2025. PMID: 40078538 Free PMC article.
-
Epidemiological Characteristics and Antimicrobial Resistance Changes of Carbapenem-Resistant Klebsiella pneumoniae and Acinetobacter baumannii under the COVID-19 Outbreak: An Interrupted Time Series Analysis in a Large Teaching Hospital.Antibiotics (Basel). 2023 Feb 22;12(3):431. doi: 10.3390/antibiotics12030431. Antibiotics (Basel). 2023. PMID: 36978298 Free PMC article.
-
Historical Overview of the Evolution of Multidrug-Resistant Gram-Negative Infections in Tunisia from 1999 to 2019.Antibiotics (Basel). 2025 Jun 29;14(7):657. doi: 10.3390/antibiotics14070657. Antibiotics (Basel). 2025. PMID: 40723960 Free PMC article.
-
Machine learning and feature extraction for rapid antimicrobial resistance prediction of Acinetobacter baumannii from whole-genome sequencing data.Front Microbiol. 2024 Jan 11;14:1320312. doi: 10.3389/fmicb.2023.1320312. eCollection 2023. Front Microbiol. 2024. PMID: 38274740 Free PMC article.
-
Cost-effectiveness analysis of ceftazidime-avibactam as definitive treatment for treatment of carbapenem-resistant Klebsiella pneumoniae bloodstream infection.Front Public Health. 2023 Feb 28;11:1118307. doi: 10.3389/fpubh.2023.1118307. eCollection 2023. Front Public Health. 2023. PMID: 36926178 Free PMC article.
References
LinkOut - more resources
Full Text Sources
Molecular Biology Databases